EVRAS
ActiveSummary
EVRAS has been active since 1977 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €57,345 and a net result of €1,560. Equity is shrinking by about 9.3% per year across the filed financial years. Its solvency ranks better than 57% of 12,519 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
04-12
Gazette deed
Reappointments: GESTIPHARMA (director) and FINPHARMA (director)Permanent representative: Pierre-Pascal Hecq · Director discharge8 facts ▸
- General meeting, 28-06-2024
- Director reappointment, GESTIPHARMA (director)
- Director reappointment, FINPHARMA (director)
- Director reappointment, GESTIPHARMA (managing director)
- Permanent representative, Pierre-Pascal Hecq
- General meeting, 18-03-2022
- Director discharge, GESTIPHARMA
- Director discharge, FINPHARMA
About the unread acts
Of the 6 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 5 have not been read yet: what they contain is neither established nor disproved here.